Leptin and aldosterone in sympathetic activity in resistant hypertension with or without Type 2 diabetes

Arquivos Brasileiros de Cardiologia

Volumn 99, Issue 1, 2012, Pages 642-648

  Boer Martins, Leandro ^a,b   Figueiredo, Valéria Nasser ^a   Demacq, Caroline ^a,b   Martins, Luiz Cláudio ^a   de Faria, Ana Paula Cabral ^a   Moraes, Carolina de Haro ^a   Heitor, Moreno ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Pharma Sector   (Brazil)

Author keywords

Aldosterone; Diabetes mellitus; Hypertension; Leptin; Sympathetic nervous system; Type 2

Indexed keywords

ALDOSTERONE; HORMONE RECEPTOR BLOCKING AGENT; LEPTIN; MINERALOCORTICOID RECEPTOR;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; ELECTROCARDIOGRAPHY; FEMALE; FREQUENCY ANALYSIS; HEART RATE VARIABILITY; HORMONE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RESISTANT HYPERTENSION; STRATIFIED SAMPLE; SYMPATHETIC TONE;

EID: 84866035085     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2012005000047     Document Type: Article

References (27)

1. McGill JB, Haffner S, Rees TJ, Sowers JR, Tershakovec AM, Weber M. Progress and controversies: treating obesity and insulin resistance in the context of hypertension. J Clin Hypertens (Greenwich). 2009;11(1):36-41.
2. Rahmouni K. Obesity, sympathetic overdrive, and hypertension: the leptin connection. Hypertension. 2010;55(4):844-5.
3. da Silva AA, do Carmo J, Dubinion J, Hall JE. The role of the sympathetic nervous system in obesity-related hypertension. Curr Hypertens Rep. 2009;11(3):206-11.
4. Acelajado MC, Calhoun DA. Aldosteronism and resistant hypertension. Int J Hypertens. 2011;2011:837817.
5. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403-19.
6. Iacobellis G, Petramala L, Cotesta D, Pergolini M, Zinnamosca L, Cianci R, et al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrinol Metab. 2010;95(5):2391-8.
7. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351(1):33-41.
8. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150(11):776-83.
9. Tsioufis C, Kordalis A, Flessas D, Anastasopoulos I, Tsiachris D, Papademetriou V, et al. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens. 2011;2011:642416.
10. Sztajzel J. Heart rate variability: a noninvasive electrocardiographic method to measure the autonomic nervous system. Swiss Med Wkly. 2004;134(35-36):514-22.
11. Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 2010;141(2):122-31.
12. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93(5):1043-65.
13. Asferg C, Mogelvang R, Flyvbjerg A, Frystyk J, Jensen JS, Marott JL, et al. Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens. 2010;23(3):327-33.
14. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-26.
15. de Souza WA, Sabha M, de Faveri Favero F, Bergsten-Mendes G, Yugar-Toledo JC, Moreno H. Intensive monitoring of adherence to treatment helps to identify "true" resistant hypertension. J Clin Hypertens (Greenwich). 2009;11(4):183-91.
16. Sociedade Brasileira de Cardiologia/Sociedade Brasileira de Hipertensão/ Sociedade Brasileira de Nefrologia. VI Diretrizes brasileiras de hipertensão. Arq Bras Cardiol. 2010;95(1 supl. 1):1-51.
17. Vanderlei LC, Pastre CM, Hoshi RA, Carvalho TD, Godoy MF. Basic notions of heart rate variability and its clinical applicability. Rev Bras Cir Cardiovasc. 2009;24(2):205-17.
18. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40(6):892-6.
19. Hayden MR, Sowers JR. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2008;3(3):129-31.
20. Yu Y, Wei SG, Zhang ZH, Gomez-Sanchez E, Weiss RM, Felder RB. Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure? Hypertension. 2008;51(3):727-33.
21. Zhang ZH, Wei SG, Francis J, Felder RB. Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: the role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol. 2003;284(4):R916-27.
22. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis. 2010;52(5):401-9.
23. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):1159-64.
24. Hall JE, Brands MW, Hildebrandt DA, Kuo J, Fitzgerald S. Role of sympathetic nervous system and neuropeptides in obesity hypertension. Braz J Med Biol Res. 2000;33(6):605-18.
25. Hirose H, Saito I, Tsujioka M, Mori M, Kawabe H, Saruta T. The obese gene product, leptin: possible role in obesity-related hypertension in adolescents. J Hypertens. 1998;16(12 Pt 2):2007-12.
26. Suter PM, Locher R, Hasler E, Vetter W. Is there a role for the ob gene product leptin in essential hypertension? Am J Hypertens. 1998;11(11 Pt 1):1305-11.
27. Rutkowski MP, Klanke CA, Su YR, Reif M, Menon AG. Genetic markers at the leptin (OB) locus are not significantly linked to hypertension in African Americans. Hypertension. 1998;31(6):1230-4.